Navigation Links
Global Study Reveals Differences in Standard of Care for Osteoporosis Across the World
Date:5/25/2008

In Europe, Less Screening and Treatment, and an Apparent Higher Prevalence

of Hip Fracture Than in North America and Australia

BARCELONA, Spain, May 25 /PRNewswire/ -- In a first-of-its-kind study in osteoporosis, one in four women surveyed from Europe, North America, and Australia reported having one or more bone fractures since the age of 45 years. Among women considered to be at high risk for a fracture, only 26% reported use of bone-saving drugs, with use reported significantly less frequently in Europe than in North America and Australia. Identifying important regional differences is just one aim of a landmark observational study, the Global Longitudinal Registry of Osteoporosis in Women (GLOW), which will monitor the health of over 60,000 older women (more than or equal to 55 yrs) worldwide for 5 years. Baseline results were presented today at the 35th European Symposium on Calcified Tissues.

For women enrolled in GLOW, fractures after the age of 45 were more prevalent in Europe than in the United States, Canada and Australia. For hip fracture specifically, a prior hip fracture was reported more frequently by women in Europe (2.1%) than by women in the United States (1.7%) or in Canada/Australia (1.4%). These potential differences will be further explored in follow-up years of the study.

"We need to understand the cause for the regional differences we observe in fracture prevalence," said Dr Robert Lindsay, Professor of Clinical Medicine at Columbia University and GLOW executive committee co-chair. "One aim of GLOW is to learn from those countries that are having the greatest success at preventing fractures and to recommend best practices that will improve the bone health and lives of millions of patients around the world."

To be eligible for this multi-national study, a woman had to be aged 55 years or older and had to have visited a primary care physician for any health reason in the two years prior to the study. Since patient recruitment for GLOW was not linked to osteoporosis, the study is meant to provide a view to the bone health and quality of care of "typical" community-dwelling women in multiple geographies.

In Europe, 51% of GLOW participants reported having a bone density test, a valuable tool for diagnosing osteoporosis. This contrasts to other geographies where testing frequency was reported at 79%. Among women considered to be at high risk of fracture, only 20% of European women were taking a bone medication versus 30% of North American/Australian women.

"Despite reliable screening methods and multiple therapeutic options being available, osteoporosis remains largely under-diagnosed and under-treated," said Professor Pierre Delmas, Professor of medicine and rheumatology at University of Lyon, France, and GLOW executive committee co-chair. "Without some improvements, the burden of fractures on our families and on our healthcare systems will only grow with the aging population."

Osteoporosis-related fractures are an international public health problem responsible for increased mortality, functional impairment and additional health care costs(i),(ii). Direct costs of osteoporotic fractures in Europe alone are expected to rise from EUR31.7 billion in 2000 to EUR76.7 billion by 2050 (iii). In women over 45 years of age, osteoporosis accounts for more days spent in a hospital than diabetes, heart attack or breast cancer(iv).

Hip fractures are the most serious of osteoporosis-related fractures, causing chronic pain, reduced mobility, disability, loss of independence and an increased risk of death(i),(ii). An estimated 179,000 men and 711,000 women in Europe suffer a hip fracture each year(iii).

GLOW is a prospective, longitudinal, observational study of women 55 years of age and older who visited a primary care physician during the two years prior to the study. Over 60,000 women have been recruited through 700 primary care physicians in 17 cities in the United States, Canada, Europe, and Australia. GLOW will gather information on osteoporosis risk factors, treatment approaches, patient behaviour, and fracture outcomes with an annual patient survey over a 5 year period.

Results reported herein are from analysis of approximately 50,200 baseline surveys. Patients were categorized as high risk for fracture based on a fracture index score of less than or equal to 5, according to Black et al(v). Bone medications included bishosphonates, raloxifene, strontium ranelate, parathyroid hormone (1-84), teriparatide, tibolone, and calcitonin.

GLOW is being conducted by The Center for Outcomes Research (COR), University of Massachusetts Medical School (UMMS), with the support of an unrestricted research grant from The Alliance for Better Bone Health. The Alliance for Better Bone Health is a collaboration between sanofi-aventis and Procter & Gamble Pharmaceuticals.

Available for comment:

Dr. Robert Lindsay

Executive committee co-chair, GLOW, Professor of Clinical Medicine, Columbia University and Chief of Internal Medicine at Helen Hayes Hospital, West Haverstraw, NY, USA

---------------------------------

(i) Osteoporosis in the European Community: A call to action. Report by the International Osteoporosis Foundation. (c) Copyright 1999-2007 IOF. Accessed 06.02.08, available from http://www.iofbonehealth.org/publications/eu-policy-report-of-2001.html

(ii) Keene GS, Parker MJ and Pryor GA. Mortality and morbidity after hip fractures. BMJ. 1993 (6914):307;1248-50

(iii) Kanis JA and Johnell O. Requirements for DXA for the management of osteoporosis in Europe. Osteoporosis Int. 2005:16; 229-38

(iv) Kanis JA, Delmas P, Burckhardt P, Cooper C and Torgerson D. Guidelines for diagnosis and management of osteoporosis. Osteoporosis Int. 1997:7; 390-406

(v) Black DM, Steinbuch M, Palermo L, et al. An assessment tool for predicting fracture risk in postmenopausal women. Osteoporosis Int. 2001:12; 519-528


'/>"/>
SOURCE University of Massachusetts Medical School
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Global Experts Explore Entire Spectrum of Aids Vaccine Development
2. Mindray to Present at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
3. Advanced Life Sciences to Present at 2007 UBS Global Life Sciences Conference
4. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
5. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
6. Clinsys Clinical Research, Inc. Announces Key Hires, Rajagopalan Srinivasan, Ph.D, to Strengthen Global Biostatistics Service Offering and Christopher Gregory, Ph.D, to Scientific Affairs
7. Jazz Pharmaceuticals to Present at UBS Global Life Sciences Conference
8. A Large-Scale Research Project by a Dutch Consortium Addressing a Global Problem
9. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
10. Allos Therapeutics to Present at the 2007 UBS Global Life Sciences Conference
11. Merrill Lynch Global Pharmaceutical, Biotech and Medtech Conference to Webcast Millennium Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... 2016 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, hematopoietic ... the results of its 2016 Annual General Meeting, which was ... China . At the Annual ... of KPMG Huazhen LLP as the independent auditors of the ...
(Date:12/8/2016)... ... December 08, 2016 , ... Lajollacooks4u, San Diego’s premier team building ... team building events, new program offerings and company expansion. , This is ... to include groups of over 30 people. Ever since, Lajollacooks4u has seen significant demand ...
(Date:12/8/2016)... , Dec. 8, 2016  Renova™ Therapeutics, ... congestive heart failure and type 2 diabetes, announced ... a novel adeno-associated virus (AAV) vector developed in ... M.D., Ph.D., at Stanford University. The company plans ... paracrine gene therapy product pipeline. ...
(Date:12/8/2016)... OXFORD, England , December 8, 2016 ... Company, has expanded its customisable SureSeq™ NGS panel range with ... - allowing fast and cost-effective study of variants in familial ... copy number variation (CNV) detection on a single small panel ... and hotspot content. This includes all exons for LDLR ...
Breaking Biology Technology:
(Date:11/30/2016)... 2016  higi SH llc (higi) announced today ... national brands, industry thought-leaders and celebrity influencers looking ... for taking steps to live healthier, more active ... higi has built the largest self-screening health station ... people who have conducted over 185 million biometric ...
(Date:11/24/2016)... , Nov. 23, 2016 Cercacor today introduced ... and their trainers non-invasively measure hemoglobin, Oxygen ... Rate, and Respiration Rate in approximately 30 seconds. Smaller ... easy and immediate access to key data about their ... a training regimen. Hemoglobin carries oxygen ...
(Date:11/17/2016)... Global Market Watch: Primarily supported by ownership types; ... Academics) market is to witness a value of US$37.1 billion ... Compounded Annual Growth Rate (CAGR) of 10.75% is foreseen from ... 2014-2020. North America is not way ... Europe at 9.56% respectively. Report Focus: ...
Breaking Biology News(10 mins):